Role of the TGF-beta/Alk5 signaling pathway in monocrotaline-induced pulmonary hypertension.

RATIONALE Pulmonary arterial hypertension is a progressive disease characterized by an elevation in the mean pulmonary artery pressure leading to right heart failure and a significant risk of death. Alterations in two transforming growth factor (TGF) signaling pathways, bone morphogenetic protein receptor II and the TGF-beta receptor I, Alk1, have been implicated in the pathogenesis of pulmonary hypertension (PH). However, the role of TGF-beta family signaling in PH and pulmonary vascular remodeling remains unclear. OBJECTIVES To determine whether inhibition of TGF-beta signaling will attenuate and reverse monocrotaline-induced PH (MCT-PH). METHODS We have used an orally active small-molecule TGF-beta receptor I inhibitor, SD-208, to determine the functional role of this pathway in MCT-PH. MEASUREMENTS AND MAIN RESULTS The development of MCT-PH was associated with increased vascular cell apoptosis, which paralleled TGF-beta signaling as documented by psmad2 expression. Inhibition of TGF-beta signaling with SD-208 significantly attenuated the development of the PH and reduced pulmonary vascular remodeling. These effects were associated with decreased early vascular cell apoptosis, adventitial cell proliferation, and matrix metalloproteinase expression. Inhibition of TGF-beta signaling with SD-208 in established MCT-PH resulted in a small but significant improvement in hemodynamic parameters and medial remodeling. CONCLUSIONS These findings provide evidence that increased TGF-beta signaling participates in the pathogenesis of experimental severe PH.

[1]  Yingling Liu,et al.  The 5‐HT transporter transactivates the PDGFβ receptor in pulmonary artery smooth muscle cells , 2007 .

[2]  P. Sehgal,et al.  Dysfunctional intracellular trafficking in the pathobiology of pulmonary arterial hypertension. , 2007, American journal of respiratory cell and molecular biology.

[3]  Alison Murphy,et al.  Inhibition of Transforming Growth Factor β Signaling Reduces Pancreatic Adenocarcinoma Growth and Invasiveness , 2007, Molecular Pharmacology.

[4]  W. Seeger,et al.  The transforming growth factor-β/Smad2,3 signalling axis is impaired in experimental pulmonary hypertension , 2007, European Respiratory Journal.

[5]  K. Chung,et al.  Effect of Transforming Growth Factor-β Receptor I Kinase Inhibitor 2,4-Disubstituted Pteridine (SD-208) in Chronic Allergic Airway Inflammation and Remodeling , 2006, Journal of Pharmacology and Experimental Therapeutics.

[6]  N. Voelkel,et al.  Apoptosis of pulmonary microvascular endothelial cells stimulates vascular smooth muscle cell growth. , 2006, American journal of physiology. Lung cellular and molecular physiology.

[7]  George H. Thomas,et al.  Aneurysm Syndromes Caused by Mutations in the TGF-β Receptor , 2006 .

[8]  D. McKean,et al.  Tenascin-C is induced by mutated BMP type II receptors in familial forms of pulmonary arterial hypertension. , 2006, American journal of physiology. Lung cellular and molecular physiology.

[9]  Wolfram Kress,et al.  A syndrome of altered cardiovascular, craniofacial, neurocognitive and skeletal development caused by mutations in TGFBR1 or TGFBR2 , 2005, Nature Genetics.

[10]  W. Seeger,et al.  Reversal of experimental pulmonary hypertension by PDGF inhibition. , 2005, The Journal of clinical investigation.

[11]  C. Heldin,et al.  Non-Smad TGF-β signals , 2005, Journal of Cell Science.

[12]  J. Loscalzo,et al.  Increased Susceptibility to Pulmonary Hypertension in Heterozygous BMPR2-Mutant Mice , 2005, Circulation.

[13]  P. Jones,et al.  Epidermal Growth Factor Receptor Blockade Mediates Smooth Muscle Cell Apoptosis and Improves Survival in Rats With Pulmonary Hypertension , 2005, Circulation.

[14]  C. Munaut,et al.  Smooth muscle cell matrix metalloproteinases in idiopathic pulmonary arterial hypertension , 2005, European Respiratory Journal.

[15]  M. Kolb,et al.  Progressive transforming growth factor beta1-induced lung fibrosis is blocked by an orally active ALK5 kinase inhibitor. , 2005, American journal of respiratory and critical care medicine.

[16]  P. Sehgal,et al.  Monocrotaline pyrrole-induced endothelial cell megalocytosis involves a Golgi blockade mechanism. , 2005, American journal of physiology. Cell physiology.

[17]  D. Kass,et al.  Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy , 2005, Nature Medicine.

[18]  A. Zaiman,et al.  Impaired transforming growth factor-beta signaling in idiopathic pulmonary arterial hypertension. , 2004, American journal of respiratory and critical care medicine.

[19]  K. Miyazono,et al.  BMPR-II heterozygous mice have mild pulmonary hypertension and an impaired pulmonary vascular remodeling response to prolonged hypoxia. , 2004, American journal of physiology. Lung cellular and molecular physiology.

[20]  D. Judge,et al.  TGF-β–dependent pathogenesis of mitral valve prolapse in a mouse model of Marfan syndrome , 2004 .

[21]  N. Morrell,et al.  Differential effects of TGF-beta1 and BMP-4 on the hypoxic induction of cyclooxygenase-2 in human pulmonary artery smooth muscle cells. , 2004, American Journal of Physiology - Lung cellular and Molecular Physiology.

[22]  L. Attisano,et al.  Regulation of the TGFβ signalling pathway by ubiquitin-mediated degradation , 2004, Oncogene.

[23]  R. Trembath,et al.  Molecular and functional analysis identifies ALK-1 as the predominant cause of pulmonary hypertension related to hereditary haemorrhagic telangiectasia , 2003, Journal of medical genetics.

[24]  Ying E. Zhang,et al.  Smad-dependent and Smad-independent pathways in TGF-β family signalling , 2003, Nature.

[25]  Jonas Larsson,et al.  Activin receptor-like kinase (ALK)1 is an antagonistic mediator of lateral TGFbeta/ALK5 signaling. , 2003, Molecular cell.

[26]  S. Black,et al.  Alterations in TGF-β1 expression in lambs with increased pulmonary blood flow and pulmonary hypertension , 2003 .

[27]  J. Massagué,et al.  Mechanisms of TGF-β Signaling from Cell Membrane to the Nucleus , 2003, Cell.

[28]  C. Heldin,et al.  Mechanisms of TGF-beta signaling in regulation of cell growth and differentiation. , 2002, Immunology letters.

[29]  A. Harf,et al.  Gelatinase expression in pulmonary arteries during experimental pulmonary hypertension. , 2001, The European respiratory journal.

[30]  R. Trembath,et al.  Altered Growth Responses of Pulmonary Artery Smooth Muscle Cells From Patients With Primary Pulmonary Hypertension to Transforming Growth Factor-&bgr;1 and Bone Morphogenetic Proteins , 2001, Circulation.

[31]  C. Heldin,et al.  Activation of the TGF-beta/activin-Smad2 pathway during allergic airway inflammation. , 2001, American journal of respiratory cell and molecular biology.

[32]  N. Voelkel,et al.  Severe pulmonary hypertension after the discovery of the familial primary pulmonary hypertension gene. , 2001, The European respiratory journal.

[33]  V. Fadok,et al.  Differential Effects of Apoptotic Versus Lysed Cells on Macrophage Production of Cytokines: Role of Proteases1 , 2001, The Journal of Immunology.

[34]  Christopher J. O’Callaghan,et al.  Mechanical Strain–Induced Extracellular Matrix Production by Human Vascular Smooth Muscle Cells: Role of TGF-&bgr;1 , 2000, Hypertension.

[35]  R. Trembath,et al.  Heterozygous germline mutations in BMPR2, encoding a TGF-β receptor, cause familial primary pulmonary hypertension , 2000, Nature Genetics.

[36]  Adrian M Heilbut,et al.  Complete reversal of fatal pulmonary hypertension in rats by a serine elastase inhibitor , 2000, Nature Medicine.

[37]  I. Stamenkovic,et al.  Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGF-beta and promotes tumor invasion and angiogenesis. , 2000, Genes & development.

[38]  V. Fadok,et al.  Ingested Apoptotic Cells in Macrophages That β Endogenous TGF-of Inflammatory Mediator Production by Transcriptional and Translational Regulation , 1999 .

[39]  R. Derynck,et al.  Transcriptional Activators of TGF-β Responses: Smads , 1998, Cell.

[40]  A. Halbower,et al.  Agarose infiltration improves morphology of cryostat sections of lung. , 1994, Laboratory investigation; a journal of technical methods and pathology.

[41]  D. Miller,et al.  Expression of transforming growth factor-beta mRNAs and proteins in pulmonary vascular remodeling in the sheep air embolization model of pulmonary hypertension. , 1994, American journal of respiratory cell and molecular biology.

[42]  L. Gold,et al.  Vascular remodeling in primary pulmonary hypertension. Potential role for transforming growth factor-beta. , 1994, American Journal of Pathology.

[43]  M. Gillespie,et al.  Temporal alterations in specific basement membrane components in lungs from monocrotaline-treated rats. , 1993, American journal of respiratory cell and molecular biology.

[44]  R. Mecham,et al.  Transforming growth factor-beta 1 is decreased in remodeling hypertensive bovine pulmonary arteries. , 1992, The Journal of clinical investigation.

[45]  H. Moses,et al.  Transforming growth factor-beta activity in sheep lung lymph during the development of pulmonary hypertension. , 1990, The Journal of clinical investigation.

[46]  S. Rosenberg,et al.  Effects of postoperative adjuvant chemotherapy and radiotherapy on ovarian function in women undergoing treatment for soft tissue sarcoma. , 1981, Journal of the National Cancer Institute.

[47]  A. Zuckerman,et al.  Induction of morphological changes in human embryo liver cells by the pyrrolizidine alkaloid lasiocarpine. , 1972, British journal of experimental pathology.

[48]  A. Zuckerman,et al.  The effect of heliotrine, a pyrrolizidine alkaloid, on human liver cells in culture. , 1969, British journal of experimental pathology.

[49]  L. B. Bull.  THE HISTOLOGICAL EVIDENCE OP LIVER DAMAGE FROM PYRROLIZIDINE ALKALOIDS , 1955 .

[50]  Robert C. Anderson,et al.  THE ACTION OF MONOCROTALINE AND RETRONECINE , 1942 .

[51]  S. Rennard,et al.  Transforming Growth Factor-β Receptor Type 1 (TGFβRI) Kinase Activity but Not p38 Activation Is Required for TGFβRI-Induced Myofibroblast Differentiation and Profibrotic Gene Expression , 2006, Molecular Pharmacology.

[52]  W. Travis,et al.  Immunohistochemical study of endothelin-1 and matrix metalloproteinases in plexogenic pulmonary arteriopathy. , 2002, Pathology, research and practice.

[53]  M. Humbert,et al.  BMPR2 haploinsufficiency as the inherited molecular mechanism for primary pulmonary hypertension. , 2001, American journal of human genetics.

[54]  P. Jones,et al.  Elastase and matrix metalloproteinase inhibitors induce regression, and tenascin-C antisense prevents progression, of vascular disease. , 2000, The Journal of clinical investigation.

[55]  D. Morin,et al.  Mechanisms and pathology of monocrotaline pulmonary toxicity. , 1992, Critical reviews in toxicology.